Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 117Carcinoma, Transitional Cell 39Testicular Neoplasms 23Urethral Neoplasms 18Testicular Germ Cell Tumor 14Ovarian Neoplasms 13Teratoma 12Prostatic Neoplasms 11Endodermal Sinus Tumor 11Seminoma 10Neoplasms 10Carcinoma, Embryonal 9Ureteral Neoplasms 8Melanoma 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Renal Cell 7Stomach Neoplasms 6Penile Neoplasms 6Neoplasm Metastasis 6Colorectal Neoplasms 6Breast Neoplasms 6Urologic Neoplasms 5Sarcoma 5Pancreatic Neoplasms 5Urothelial Cancer 4Lung Neoplasms 4Central Nervous System Neoplasms 4Wilms Tumor 3Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3

Interventions

tislelizumab 2Cystectomy 2vistusertib 1toripalimab 1olaparib 1liposomal doxorubicin 1durvalumab 1disitamab vedotin 1danvatirsen 1adavosertib 1Surgical Procedures, Operative 1Rutin 1Radiation 1RC48 antibody 1Neoadjuvant Therapy 1Gemcitabine 1Cisplatin 1Chemoradiotherapy 1AZD4547 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muscle Invasive Bladder Cancer × Cisplatin × Genitourinary × Clear all
NCT06916494 2025-04-10

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

First Affiliated Hospital of Chongqing Medical University

Phase 1 Recruiting
10 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡